ImmunityBio, Inc. IBRX
6.67 USD -0.08 (-1.11%)
At closeNov 11, 2026, 4:32 PM EST
6.67 0.00 0.00%
After hours · Nov 11, 4:32 PM ET
6.51 Day range 6.85
1.95 52-week range 12.43
- YTD
- +236.87%
- 1 year
- +211.68%
News
businesswire.com New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced findings from a national survey of military service members and…
businesswire.com ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced members of the senior leadership team will speak at the upcoming…
zacks.com IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18% ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.
fool.com Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy? ImmunityBio's quarterly product sales rose 53% from a year earlier, but they slipped from the prior quarter and missed Wall Street's estimate. Even after Monday's drop, the stock trades at roughly 39…
benzinga.com ImmunityBio Reports Wider Quarterly Loss ImmunityBio Inc. (NASDAQ:IBRX) stock is trading lower on Monday after the company's third-quarter earnings missed expectations.
benzinga.com ImmunityBio Reports Wider Quarterly Loss ImmunityBio stock falls as Q3 revenue misses estimates, despite positive ANKTIVA bladder cancer trial results and Israeli approval.
zacks.com ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.
benzinga.com ImmunityBio Q3 Adj. EPS $(0.09) Misses $(0.08) Estimate, Sales $48.841M Miss $59.250M Estimate ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 28.57 percent decrease over losses of…
benzinga.com ImmunityBio Reports Expanded ANKTIVA Approval And Global Market Expansion Across 35 Countries Label Expansion and Global ProgressFDA Expanded Approval: On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved our supplemental Biologics License Application (sBLA) expanding the…
businesswire.com ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial…
benzinga.com ImmunityBio And Rafa Laboratories Say Israeli MoH Grants Approval For ANKTIVA, Indicated In Combination With BCG For Treatment Of Adult Patients With BCG-Unresponsive NMIBC With CIS With Or Without Papillary Tumors Partnership brings first-in-class IL-15 receptor agonist immunotherapy to patients in IsraelIsraeli Ministry of Health grants approval for ANKTIVA® (nogapendekin alfa inbakicept) in combination with…
businesswire.com ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ JERUSALEM & CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health…- benzinga.com ImmunityBio Says ANKTIVA Plus BCG Meets Primary Endpoint In Phase 3 NMIBC Trial, Supports Planned FDA Filing ANKTIVA® plus BCG met the primary efficacy endpoint in the randomized registrational trial of 370 subjects comparing intravesical ANKTIVA plus BCG with BCG alone; additional study details will be…
businesswire.com ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in…
benzinga.com ImmunityBio Treats First Patient In Europe With ANKTIVA In Combination With Bacillus Calmette-Guérin ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with ANKTIVA® (nogapendekin alfa inbakicept) in…
businesswire.com ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ CULVER CITY, Calif. & DUBLIN--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with…
benzinga.com Jim Cramer Calls Celsius 'A Second-Rate Monster,' Says Stick With the Original Jim Cramer called ImmunityBio a strong speculative buy, favored Monster over Celsius, avoided USA Rare Earth and liked Glacier Bancorp.- benzinga.com ImmunityBio Anticipates Reporting Topline Results In November 2026, Remains On Track To Submit sBLA To FDA In Q4 2026 For ANKTIVA Plus BCG In Patients With BCG-Naïve NMIBC Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle…
benzinga.com ImmunityBio Completes Database Lock For Cohort A Of QUILT-2.005, Randomized, Controlled, Registrational Trial Evaluating ANKTIVA In Combination With BCG Versus BCG Alone In Patients With BCG-Naïve NMIBC Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle…
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment New data show ImmunityBio's ANKTIVA combined with BCG provides durable responses and high survival rates in unresponsive bladder cancer.
benzinga.com ImmunityBio Announces Data From Its Phase 2/3 QUILT-3.032 Trial Of ANKTIVA In Combination With Bacillus Calmette-Guerin Demonstrates 71% Complete Response Rate In Participants With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The…
benzinga.com Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $14 Jefferies analyst Kelly Shi maintains ImmunityBio (NASDAQ:IBRX) with a Buy and raises the price target from $12 to $14.
benzinga.com ImmunityBio Stock Climbs Thursday: What's Going On? ImmunityBio shares are trading higher Thursday after the FDA approved expansion for its bladder cancer therapy ANKTIVA.- benzinga.com HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.
benzinga.com Why Is ImmunityBio Stock Gaining Wednesday? ImmunityBio (IBRX) stock jumps over 5% following FDA expanded approval for Anktiva in NMIBC bladder cancer treatment. Get details.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
benzinga.com ImmunityBio Stock Jumps: What's Going On? ImmunityBio Inc. (NASDAQ: IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10)…
benzinga.com ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug ImmunityBio secures UAE marketing authorization for ANKTIVA across two cancer indications, expanding treatment options for NMIBC and NSCLC.
benzinga.com Reported Earlier, ImmunityBio's ANKTIVA Wins UAE Nod For NSCLC After QUILT-3.055 Trial Showed 14.6-Month Median Overall Survival In Checkpoint-Refractory Patients The UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to…
benzinga.com Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now Lucid, Figma, SoundHound and Ondas are among the most heavily shorted stocks in the market right now.
benzinga.com Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation' Jim Cramer recommended buying CAVA Group (CAVA), citing its potential and tasty, clean, and fun concept, also likes Trulieve Cannabis (TRLV) and advised holding onto Ashland (ASH).- benzinga.com HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.
- benzinga.com ImmunityBio Presents Data At American Society Of Clinical Oncology Annual Meeting About Its Phase 3 Studies In Advanced Non-Small Cell Lung Cancer ImmunityBio, Inc. ((
- benzinga.com ImmunityBio Announces Preliminary Results From News Economic Analysis Showing That Anktiva Plus Bacillus Calmette–Guérin Achieved A Lower Cost Per Sustained Complete Responder ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced preliminary results from a new health economic analysis demonstrating that ANKTIVA® (nogapendekin alfa…
benzinga.com ImmunityBio Announces New Survey Data Showing Diverse Treatment Preferences And Priorities Of Patients With Bacillus Calmette–Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026, May 17–20, 2026, at the Pennsylvania Convention Center in Philadelphia,…
benzinga.com TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.
benzinga.com ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data showing durable bladder cancer outcomes.- benzinga.com HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.
- benzinga.com Reported Earlier, ImmunityBio Says FDA Accepted ANKTIVA Plus Bacillus Calmette-Guerin Filing For Papillary Non-Muscle Invasive Bladder Cancer Following Workshop Support And National Comprehensive Cancer Network Guidance Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary diseaseFDA noted in its filing communication that the supplemental BLA accepted for…
benzinga.com ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies ImmunityBio reported AUA 2026 data showing ANKTIVA plus BCG outperformed rival therapies in key bladder cancer measures.- benzinga.com ImmunityBio Announces Results From Two ITC Analyses Presented At 2026 AUA Annual Meeting Evaluating Nogapendekin Alfa inbakicept-pmln Plus BCG NAI+BCG versus Nadofaragene Results:NAI+BCG treated patients were twice as likely to achieve a complete response (CR) at any point of the study versus nadofaragene firadenovec-vncg in…
benzinga.com ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership ImmunityBio secures exclusive U.S. rights to Japan BCG Lab's Tokyo strain of BCG, aiming to end a decade-long U.S. supply shortage.- benzinga.com ImmunityBio Secures Five US Patents Covering Combination Of IL-15 Receptor Agonist ANKTIVA With Bacillus Calmette-Guérin For Treatment Of Cancer Five issued U.S. patents cover the combination of ImmunityBio's IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer treatment, with terms extending…
- benzinga.com Reported Saturday, ImmunityBio Secures Exclusive US Rights To Tokyo-172 BCG After Phase 3 Trial Shows Non-Inferior Efficacy To TICE BCG Positive Phase III readout of National Cancer Institute-sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tokyo strain of BCG (Tokyo-172 BCG) versus TICE BCG…
benzinga.com ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum ImmunityBio shares fall after Q1 losses misses estimates despite strong ANKTIVA sales growth and updated bladder cancer treatment guidelines.- benzinga.com UPDATE: ImmunityBio Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 20 percent increase over losses of $(0.10)…